Research progress of paclitaxel drug formulations
10.3760/cma.j.issn.1008-6706.2016.02.042
- VernacularTitle:紫杉醇药物制剂的研究进展
- Author:
Lizhi ZHANG
- Publication Type:Journal Article
- Keywords:
Ovayian neoplasms;
Breast neoplasms;
Paclitaxel
- From:
Chinese Journal of Primary Medicine and Pharmacy
2016;23(2):303-305
- CountryChina
- Language:Chinese
-
Abstract:
Paclitaxel is an antimicrotubule agent indicated as first-line therapy for the treatment of advanced carcinoma of the ovary and breast cancer.Oral administration of paclitaxel is preferred as it is convenient to use in hospital and reduces costs.However,due to the low oral bioavailability of paclitaxel,most commercially available for-mulations are injections.This review presents the progress of developed paclitaxel injection and oral formulations to enhance the bioavailability of paclitaxel.
